Moderna and Merck report results for mRNA melanoma vaccine
A late-stage clinical trial shows that an mRNA-based vaccine developed by Moderna and Merck reduced the risk of melanoma recurrence or death by 42 percent.
Pharmaceutical companies Moderna and Merck have released data indicating that their personalized mRNA vaccine reduced the risk of death or recurrence in melanoma patients by 42 percent compared to standard care. The findings stem from a late-stage clinical trial focused on the most aggressive form of skin cancer.
The companies are currently in discussions with regulatory authorities to pursue formal approval for the therapy. This development signals a potential shift in oncology, as it leverages mRNA technology to create treatments tailored to the specific genetic profile of a patient’s tumor.
Moderna CEO Stéphane Bancel stated that the trial results support the potential for mRNA technology to provide individualized cancer treatments. Should the vaccine receive regulatory clearance, it would offer a new clinical pathway for patients at high risk of cancer progression.